Non-hormonal systemic therapy in men with hormone-refractory prostate cancer and metastases: a systematic review from the Cancer Care Ontario Program in Evidence-based Care's Genitourinary Cancer Disease Site Group

Table 7 Other chemotherapy trials.

Trial	N randomized/Evaluable	Treatments (dose) and schedule	Duration
Weissbach, 1998 [88]	NR/175	epirubicin (25 mg/m²) iv q mo	NR
		EMP (560 mg) daily
		mitomycin C (10 mg/m²) iv q mo
Newling, 1993 [77]	171/161	mitomycin-C (15 mg/m²) iv q 6 wks	to progression
		EMP (560 to 700 mg)* po daily
Murphy, 1988 [75]	180/152	doxorubicin (50 mg/m²) iv q 3 wks cyclophosphamide (500 mg/m²) iv q 3 wks	to progression
		cisplatin (50 mg/m²) iv q 3 wks 5-FU (500 mg/m²) iv q 3 wks cyclophosphamide (500 mg/m²) iv q 3 wks
		methotrexate (100 mg/m²) iv (2 divided doses) q 2 wks
Loening, 1983 [78]	189/158	methotrexate (100 mg/m²) iv (two divided doses) q wk	12 wks
		cisplatin (60 mg/m²) iv (d1,4,21,24), then once monthly
		EMP (600 mg/m²) po daily (3 divided doses)

*Dose of estramustine escalated to 700 mg if 560 mg dose was tolerated for two weeks.
Abbreviations: 5-FU – 5- fluorouracil; d – day; EMP – estramustine phosphate; iv – intravenous; m² - meters squared; mg – milligrams; mo – month; N – number; NR – not reported; po – per oral; q – every; wk(s) – week (s).

ISSN: 1471-2407